Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care

5192 - Long term follow-up of the MRC TE23 randomized phase II trial of intensive induction chemotherapy (CBOP/BEP) in poor prognosis germ cell tumours (GCT) (CRUK/05/014; ISRCTN53643604)

Date

22 Oct 2018

Session

Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care

Topics

Tumour Site

Malignant Germ-Cell Tumours of the Adult Male

Presenters

Robert Huddart

Citation

Annals of Oncology (2018) 29 (suppl_8): viii303-viii331. 10.1093/annonc/mdy283

Authors

R.A. Huddart1, F. Cafferty2, J. White3, J. Shamash4, I.M. Hennig5, M. Cullen6, S. Stenning2

Author affiliations

  • 1 Radiotherapy And Imaging, Royal Marsden Hospital Institute of Cancer Research, SM2 5NG - Sutton/GB
  • 2 Mrc Clinical Trials Unit At Ucl, UCL, London/GB
  • 3 Medical Oncology, Beatson West of Scotland Cancer Centre, G12 0YN - Glasgow/GB
  • 4 Dept Of Medical Oncology, St Bartholomew's Hospital, London/GB
  • 5 Department Of Clinical Oncology, Nottingham University Hospitals NHS Trust-City Hospital Campus, NG5 1PB - Nottingham/GB
  • 6 Dept Of Medical Oncology, Queen Elizabeth-University Hospital Birmingham NHS Foundation Trust, B15 2TH - Birmingham/GB
More

Abstract 5192

Background

Up to 50% of men with poor prognosis non-seminoma GCT die with standard BEP chemotherapy. An intensive regimen, CBOP/BEP (carboplatin, bleomycin, vincristine, cisplatin/BEP), met response targets in a phase II, multicentre, open-label, randomized trial (74% with complete response or partial response marker negative, 90% CI 61% to 85%; primary outcome). Here, we report long term outcomes and prognostic factors.

Methods

Patients with extracranial GCT and IGCCCG poor prognosis features were randomised to 4xBEP or CBOP/BEP (2xCBOP, 2xBO, 3xBEP with bleomycin dose 15,000iu). Low-dose, stabilising chemotherapy prior to entry was permitted. This analysis focuses on progression-free survival (PFS), overall survival (OS) and toxicity (all secondary outcomes), and exploratory analysis of prognostic factors and the impact of marker decline (as defined in GETUG13).

Results

89 patients (43 CBOP/BEP) were randomised. After median 63 months follow-up, 3-year PFS is 55.7% (95% CI 39.7%, 69.0%) for CBOP/BEP arm, 38.7% (24.7%, 52.4%) for BEP (HR 0.59 (0.33, 1.06), p = 0.079). 3-year OS is 65.0% (48.8%, 77.2%) and 58.5% (43.0%, 71.2%) respectively (HR 0.79 (0.41, 1.52), p = 0.49). 12-month toxicity was affected by subsequent treatments, with no clear differences between arms. There was no grade ≥3 toxicity in the CBOP/BEP arm. In multivariate models, use of pre-protocol chemotherapy was the only factor associated with poorer PFS (HR2.09 (1.14, 3.81), p = 0.017). Mediastinal primary (HR 2.13 (1.02, 4.46), p = 0.045) and use of pre-protocol chemotherapy (HR 3.40 (1.74, 6.63), p < 0.001) were associated with poorer OS. Unfavourable marker decline, in 60 (70%) patients, was not associated with other prognostic factors, nor with long term outcomes (HR 0.82 (0.44, 1.53), p = 0.54 for PFS).

Conclusions

The trial was not powered to compare PFS and OS, but PFS results for CBOP/BEP are promising, and similar to the intensive arm of GETUG13. Impact on OS was less clear (and will be affected by subsequent therapy). Use of pre-protocol chemotherapy was associated with poorer outcomes. Further study in an international phase III trial is warranted.

Clinical trial identification

ISRCTN53643604.

Legal entity responsible for the study

Medical Research Council, UK.

Funding

Cancer Research UK (grant no CRUK/05/014).

Editorial Acknowledgement

Not applicable

Disclosure

R.A. Huddart: Stock or other ownership interests: Cancer Centre London LLP; Consulting or advisory role: MSD, Roche, Bristol-Myers Squibb; Speaker’s bureau: Roche, Elekta; Research funding: MSD, Elekta; Travel expenses: Roche, MSD. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.